Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCX872-B in pancreatic adenocarcinoma
NCT02345408Phase 1Completed
- Sponsor
- Amgen
- Start
- Feb 2015
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of ccx872-b in pancreatic adenocarcinoma (PDAC), sponsored by Amgen. Primary endpoints: Progression-Free Survival at 24 weeks and Incidence of Grade 3 or 4 Adverse Events at 24 weeks. Started Feb 2015; status: completed.
02
Drugs
ccx872-b
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02345408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02345408.